Dancann Pharma A/S

Equities

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
0.065 ^DKK	+38.30%		+19.05%	+116.67%

06-01	DanCann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-29	Dancann Pharma Plans Up to DKK19 Million Rights Issue	MT

Dancann Pharma A/S Appoints John M. Frellsen as Chief Commercial Officer

March 31, 2021 at 02:00 am

DanCann Pharma A/S announced that John M. Frellsen has been officially appointed as chief commercial officer. John M. Frellsen has been acting as interim Chief Commercial Officer for the last six months and will continue as permanent Chief Commercial Officer at DanCann Pharma. John M. Frellsen's employment with the company will commence in the beginning of April.

Latest news about Dancann Pharma A/S

DanCann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	06-01	CI
Dancann Pharma Plans Up to DKK19 Million Rights Issue	03-29	MT
DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	02-28	MT
DanCann Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
DanCann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025	12-20	CI
Dancann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
DanCann Pharma Issues New Shares For Debt Conversion	11-23	MT
DanCann Pharma Issues New Shares Following Debt Conversion	23-10-04	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-09-26	MT
Dancann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
DanCann Mulls Sale of Production Facility Amid Shift in Business Strategy; Shares Plunge 13%	23-08-31	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-08-21	MT
Dancann Pharma Lands DKK7 Million Debt Financing From Nordic Growth Fund; Shares Up 11%	23-07-18	MT
Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval	23-06-01	CI
Dancann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member	23-05-30	CI
Dancann Pharma Expects Final Danish Approval for Biotech Pharm1 Facility by End-summer	23-05-26	MT
Dancann Pharma in Advanced Talks for DKK12 Million Convertible Loan Deal	23-05-26	MT
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-12	CI
Dancann Pharma A/S Auditor Raises 'Going Concern' Doubt	23-05-11	CI
DanCann Pharma to Distribute Prescription Cannabinoid-based Medications in Scandinavian Markets	23-05-09	MT
Dancann Pharma A/S Provides Positive Insight on Progress of Cannabis Bulk Product Approval	23-03-14	CI
Dancann Pharma A/S and Canngros Aps Open Office in Odense	23-02-23	CI
DanCann Pharma Hires New CFO	23-01-04	MT

Chart Dancann Pharma A/S

Duration

Period

More charts

Company Profile

Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DANCANN PHARMA A/S	+116.67%	1.57M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs